Boston Scientific (BSX) May option implied volatility into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Boston Scientific (BSX) PT Raised to $77 at Oppenheimer
April 25, 2024 10:00 AM EDTOppenheimer analyst Steven Lichtman raised the price target on Boston Scientific (NYSE: BSX) to $77.00 (from $68.00) while maintaining a Outperform rating.
The analyst comments "BSX delivered 1Q24 sales meaningfully ahead of the Street (13% organic y/y). EPS was also beat ($0.56 versus our/Street's... More
Boston Scientific (BSX) PT Raised to $82 at Wells Fargo
April 25, 2024 5:23 AM EDTWells Fargo analyst Lawrence Biegelsen raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $72.00) while maintaining a Overweight rating.
The analyst comments "Today (4/24), BSX reported Q1 rev/EPS ahead of Street and raised 2024 rev guidance by 250bps at the mdpt to 10-12%.... More
Boston Scientific (BSX) PT Raised to $80 at BTIG
April 24, 2024 3:14 PM EDTBTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $80.00 (from $74.00) while maintaining a Buy rating.
The analyst comments "After a record-setting 2023, Boston Scientific is starting 2024 at an even faster pace. BSX reported Q1 revenue of $3.856B (+13.8% y/y rep., +13.1% org.) and adj. EPS of $0.56 (consensus $3.684B and $0.51), well above its guidance... More

